Pasi Jänne, MD, PhD, elaborates on EGFR exon 20 insertions in non-small cell lung cancer

Dr. Jänne, Director, Lowe Center for Thoracic Oncology, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses the incidence of EGFR exon 20 insertions in NSCLC (non-small cell lung cancer), whether these patients have worse morbidity, and if EGFR exon 20 insertions are actionable mutations.